Cite
Rathod KS, Antoniou S, Avari P, et al. Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients. JRSM Cardiovasc Dis. 2017;6:2048004017734431doi: 10.1177/2048004017734431.
Rathod, K. S., Antoniou, S., Avari, P., Ding, N., Wright, P., Knight, C., Jain, A. K., Mathur, A., Smith, E. J., Weerackody, R., Wragg, A., & Jones, D. A. (2017). Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients. JRSM cardiovascular disease, 62048004017734431. https://doi.org/10.1177/2048004017734431
Rathod, K S, et al. "Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients." JRSM cardiovascular disease vol. 6 (2017): 2048004017734431. doi: https://doi.org/10.1177/2048004017734431
Rathod KS, Antoniou S, Avari P, Ding N, Wright P, Knight C, Jain AK, Mathur A, Smith EJ, Weerackody R, Wragg A, Jones DA. Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients. JRSM Cardiovasc Dis. 2017 Oct 05;6:2048004017734431. doi: 10.1177/2048004017734431. eCollection 2017. PMID: 29051816; PMCID: PMC5637964.
Copy
Download .nbib